Assessment of Warfarin Dosing Requirements After Bariatric Surgery in Patients Requiring Long-Term Warfarin Therapy

被引:31
|
作者
Irwin, Adriane N. [1 ]
McCool, Kathleen H. [1 ,2 ]
Delate, Thomas [1 ,2 ]
Witt, Daniel M. [1 ,2 ]
机构
[1] Kaiser Permanente Colorado, Dept Pharm, Aurora, CO USA
[2] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Aurora, CO USA
来源
PHARMACOTHERAPY | 2013年 / 33卷 / 11期
关键词
anticoagulation; warfarin; bariatric surgery; gastric bypass; HEART-VALVE REPLACEMENT; GASTRIC BYPASS; ANTICOAGULATION THERAPY; SENSITIVITY; OBESITY; COMPLICATIONS;
D O I
10.1002/phar.1307
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Study ObjectiveTo quantify the change in weekly warfarin dose after bariatric surgery in patients requiring long-term warfarin therapy. DesignRetrospective matched-cohort study. SettingAnticoagulation management service in an integrated health care delivery system. PatientsPatients receiving long-term warfarin anticoagulation who underwent bariatric surgery between January 1, 1996, and December 31, 2010 (27 patients), were matched by date of surgery (2years), age (5years), and target international normalized ratio (INR) range to patients receiving long-term anticoagulation therapy who underwent other abdominal surgical procedures: cholecystectomy or endoscopic retrograde cholangiopancreatography (59 patients [control group]). Measurement and Main ResultsThe main end point was change in postoperative warfarin dose from baseline (preoperative dose), measured at weekly postoperative intervals from weeks 1 to 8 and again at months 3 and 6. After surgery, patients in the bariatric surgery group had statistically significant decreases in weekly warfarin doses compared with preoperative dose at all postoperative time points (week 1 dose vs preoperative dose, p<0.01; doses at all other time points vs preoperative dose, p<0.001), except at 6months (p>0.05). No statistically significant decreases in warfarin dose were detected at any postoperative time points in the control group. Twenty patients (74.1%) in the bariatric surgery group experienced a 20% or more decrease in weekly warfarin dose compared with 19 patients (32.2%) in the control group (p=0.004). No significant differences in warfarin-related adverse events were noted between groups. ConclusionWeekly warfarin doses decreased in the immediate postoperative period in anticoagulated patients after bariatric surgery but returned to their preoperative doses after approximately 6months. A similar pattern was not observed in patients in the control group who underwent other types of abdominal surgery. Compared with preoperative anticoagulation control, this resulted in reduced anticoagulation control despite close INR monitoring. If a causal relationship between bariatric surgery and warfarin sensitivity is established in future research, developing and validating a postbariatric surgery warfarin-dosing algorithm would be valuable.
引用
收藏
页码:1175 / 1183
页数:9
相关论文
共 50 条
  • [41] Long-term treatment with warfarin in Chinese population
    Chenhsu, RY
    Chiang, SC
    Chou, MH
    Lin, MF
    ANNALS OF PHARMACOTHERAPY, 2000, 34 (12) : 1395 - 1401
  • [42] Socioeconomic implications of long-term warfarin use
    Menzin, J
    Foster, T
    Audette, R
    DISEASE MANAGEMENT & HEALTH OUTCOMES, 2004, 12 (06) : 385 - 392
  • [43] LONG-TERM WARFARIN TREATMENT IN ARTERY DISEASE
    GALLUS, AS
    BLOOD REVIEWS, 1988, 2 (02) : 95 - 101
  • [44] Anticoagulation management of patients with long-term warfarin therapy after valve replacement during the perioperative period of pacemaker implantation
    Han, Zhi-Hong
    Ren, Xue-Jun
    Wang, Ye
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2013, 6 (07): : 594 - 598
  • [45] Trabecular bone score (TBS) and bone mineral density in patients with long-term therapy with warfarin
    Oberger Marques, Julia Vieira
    Nalevaiko, Jeferson Zanovelli
    Oliveira, Matheus Felipe
    Passos Raetsch, Arthur William
    Marques, Gustavo Lenci
    Petterle, Ricardo Rasmussen
    Moreira, Carolina A.
    Cochenski Borba, Victoria Zeghbi
    ARCHIVES OF OSTEOPOROSIS, 2020, 15 (01)
  • [46] Long-term outcome after endoscopic stent therapy for complications after bariatric surgery
    Atif Iqbal
    Brent Miedema
    Archana Ramaswamy
    Nicole Fearing
    Roger de la Torre
    Youngju Pak
    Caleb Stephen
    Klaus Thaler
    Surgical Endoscopy, 2011, 25 : 515 - 520
  • [47] Long-term outcome after endoscopic stent therapy for complications after bariatric surgery
    Iqbal, Atif
    Miedema, Brent
    Ramaswamy, Archana
    Fearing, Nicole
    de la Torre, Roger
    Pak, Youngju
    Stephen, Caleb
    Thaler, Klaus
    SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, 2011, 25 (02): : 515 - 520
  • [48] Long-Term Outcomes in Bariatric Surgery Patients
    Schuh, Leslie M.
    Creel, David
    Stote, Joseph
    Hudson, Katharine
    Jung, Alison
    Whetstone, Catherine
    Cacucci, Brenda
    Diaz, David
    Evanson, Christopher M.
    Huse, John M.
    Inman, Margaret
    Kaderabek, Douglas
    OBESITY, 2011, 19 : S191 - S192
  • [49] Long-Term Persistence of Newly Initiated Warfarin Therapy in Chinese Patients With Nonvalvular Atrial Fibrillation
    Wang, Zhi-Zun
    Du, Xin
    Wang, Wei
    Tang, Ri-Bo
    Luo, Jing-Guang
    Li, Chao
    Chang, San-Shuai
    Liu, Xiao-Hui
    Sang, Cai-Hua
    Yu, Rong-Hui
    Long, De-Yong
    Wu, Jia-Hui
    Bai, Rong
    Liu, Nian
    Ruan, Yan-Fei
    Dong, Jian-Zeng
    Ma, Chang-Sheng
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2016, 9 (04): : 380 - 387
  • [50] SAFETY OF INTRAMUSCULAR INFLUENZA IMMUNIZATION AMONG PATIENTS RECEIVING LONG-TERM WARFARIN ANTICOAGULATION THERAPY
    RAJ, G
    KUMAR, R
    MCKINNEY, WP
    ARCHIVES OF INTERNAL MEDICINE, 1995, 155 (14) : 1529 - 1531